Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Free Cash Flow (2018 - 2025)

Exagen (XGN) has disclosed Free Cash Flow for 8 consecutive years, with -$3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 2215.91% year-over-year to -$3.1 million, compared with a TTM value of -$14.3 million through Dec 2025, down 3.42%, and an annual FY2025 reading of -$14.3 million, down 3.42% over the prior year.
  • Free Cash Flow was -$3.1 million for Q4 2025 at Exagen, down from $2.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $9.0 million in Q4 2023 and bottomed at -$10.8 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$4.8 million, with a median of -$4.9 million recorded in 2021.
  • The sharpest move saw Free Cash Flow soared 270.84% in 2023, then crashed 2215.91% in 2025.
  • Year by year, Free Cash Flow stood at -$6.6 million in 2021, then grew by 20.1% to -$5.3 million in 2022, then skyrocketed by 270.84% to $9.0 million in 2023, then plummeted by 101.47% to -$132000.0 in 2024, then plummeted by 2215.91% to -$3.1 million in 2025.
  • Business Quant data shows Free Cash Flow for XGN at -$3.1 million in Q4 2025, $2.7 million in Q3 2025, and -$3.1 million in Q2 2025.